In patients with metastatic breast cancer (mBC) who progress after first-line treatment of CDK4/6 and aromatase inhibitors ...
The FDA has expanded the approval of Hologic’s Aptima human papillomavirus (HPV) assay for clinician-collected primary ...
In an interview with Targeted Oncology, Sarbajit Mukherjee, MD, GI medical oncologist at Baptist Health Miami Cancer ...
A recent study reveals significant progress in biomarker testing for lung cancer in community settings, highlighting the need ...
The episode focuses on the refinement of CLL therapy, moving away from traditional chemoimmunotherapy toward targeted ...
The FDA has granted fast track designation to the investigational oncolytic virus immunotherapy pelareorep (Reolysin) in combination with bevacizumab (Avastin) and FOLFIRI (leucovorin, fluorouracil, ...
The landscape of triple-negative breast cancer (TNBC) is shifting rapidly. What was once a landscape dominated by standard cytotoxic chemotherapy is now a complex map of immunotherapy, PARP inhibitors ...
During a live event, Sumanta K. Pal and other oncologists discuss the safety and efficacy of belzutifan for advanced renal ...
The sBLA is supported by results from the pivotal phase 3 TROPION-Breast02 clinical trial (NCT05374512), which evaluated the ...
A new drug application (NDA) and a biologics license application (BLA) have been resubmitted and accepted by the FDA for ...
QTX-2101, an oral arsenic trioxide, received FDA fast track designation for acute promyelocytic leukemia, aiming to simplify ...
Discover how antibody-drug conjugates (ADCs) are transforming treatment strategies for gastrointestinal cancers, enhancing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results